SCHEDULE: Gilead Increases Stake in Assembly Biosciences

Gilead Sciences has increased its beneficial ownership in Assembly Biosciences to 25.1% following a recent public offering.

Summary

• Gilead Sciences, Inc. acquired an additional 471,698 shares of Assembly Biosciences common stock.
• The purchase was made on May 26, 2026, as part of an underwritten public offering.
• Total consideration for the additional shares was approximately $12,499,997.
• Gilead now holds a total of 4,977,089 shares, representing a 25.1% stake in the issuer.
• The ownership percentage is based on 19,816,995 total outstanding shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal of institutional confidence, as a major industry player is actively increasing its financial commitment to the company.

Positives

• Demonstrates continued strategic commitment from a major industry partner (Gilead Sciences).
• The investment was funded through Gilead's existing cash resources, indicating strong liquidity.
• Maintains a significant 25.1% equity position, signaling long-term confidence in the issuer's pipeline.

Negatives

• The acquisition increases the concentration of ownership, which may limit the free float of shares.
• The issuer remains subject to the strategic influence of a single large shareholder.

Risks

• Beneficial ownership limitations on existing warrants prevent immediate exercise if they exceed 19.99% thresholds.
• Reliance on the continued partnership and financial support of Gilead Sciences.
• Market volatility associated with the biotechnology sector and the issuer's clinical development progress.

Future Outlook

The filing does not provide specific forward-looking guidance for the issuer, but confirms Gilead's ongoing role as a major shareholder and strategic partner.

Management Comments

• The reporting person confirms the information set forth in the statement is true, complete, and correct as of May 27, 2026.

Industry Context

StockSavvy.ai notes that this move is consistent with the broader trend of large-cap pharmaceutical companies (Big Pharma) deepening their equity stakes in smaller biotech partners to secure rights to innovative drug pipelines and mitigate development risks.

Comparison to Industry Standards

• The 25.1% stake is a significant 'cornerstone' position, common in strategic biotech collaborations.
• The use of warrants with beneficial ownership limitations is a standard mechanism to manage regulatory reporting requirements and control thresholds.

Related Party Transactions

• Gilead Sciences, Inc. is a significant shareholder and strategic partner of the issuer.

Stakeholder Impact

• Shareholders: Increased validation of the company's value proposition by a major industry player.
• Creditors: Potential for increased financial stability due to the backing of a large-cap partner.

Next Steps

• Continued monitoring of Gilead's holdings for further changes in ownership.
• Potential exercise of warrants subject to the 19.99% beneficial ownership limitation.

Key Dates

Recommendation

The increase in stake by a major partner is a positive indicator of long-term value, but the stock's performance will remain heavily tied to clinical trial outcomes rather than just ownership structure.

Keywords

Gilead Sciences, Assembly Biosciences, Schedule 13D, Biotechnology, Equity Investment, SEC Filing